Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: March 3, 2026
Reporting Period: Event-based report regarding activities on March 1, 2026.
Business Context: The Company is an emerging growth company focused on clinical diagnostics for asthma and COPD. This filing announces the presentation of a research poster at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2026 annual meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is an event-driven report and does not contain financial statements or quantitative financial data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The material event is the dissemination of clinical research findings regarding the use of sputum as a diagnostic tool to match patients with effective therapies and monitor inflammatory changes.
Guidance, Outlook, and Management Commentary
- Management Commentary: The Company presented a poster titled "Sputum as a Diagnostic Tool for the Treatment of Asthma" at the AAAAI 2026 annual meeting in Philadelphia, PA.
- Strategic Outlook: The research aims to assist physicians in improving patient outcomes and lowering healthcare costs through better monitoring of inflammatory changes over time.
- Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
- Unusual Items: None reported.
Investor Verification Checklist
- Verify the content of the attached press release (Exhibit 99.1) and the research poster (Exhibit 99.2) for specific clinical data.
- Confirm the Company's status as an emerging growth company and its listing on the Nasdaq Capital Market under symbols BIAF and BIAFW.
- Review subsequent filings for any financial impact or commercialization plans resulting from the AAAAI 2026 presentation.